Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantheus Holdings (NQ: LNTH )

115.45 +7.47 (+6.92%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,720,241
Open 109.00
Bid (Size) 112.46 (10)
Ask (Size) 119.46 (1)
Prev. Close 107.98
Today's Range 108.67 - 118.21
52wk Range 50.20 - 126.89
Shares Outstanding 67,604,097
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Peering Into Lantheus Holdings's Recent Short Interest
Via Benzinga
Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
From Lantheus Holdings, Inc.
Via GlobeNewswire

Performance

YTD
+82.96%
+82.96%
1 Month
+8.30%
+8.30%
3 Month
+16.58%
+16.58%
6 Month
+52.89%
+52.89%
1 Year
+79.21%
+79.21%

More News

Read More
Jim Cramer Likes Cava Group, Calls This Utilities Stock 'Terrific'
Via Benzinga
NASDAQ:LNTH, a strong growth stock, setting up for a breakout.
Via Chartmill
NASDAQ:LNTH, a strong growth stock, setting up for a breakout.
Via Chartmill
Why NASDAQ:LNTH Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
NASDAQ:LNTH is not too expensive for the growth it is showing.
Via Chartmill
Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
For those who appreciate growth without the sticker shock, NASDAQ:LNTH is worth considering.
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:LNTH is worth considering.
Via Chartmill
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
From Lantheus Holdings, Inc.
Via GlobeNewswire
NASDAQ:LNTH stands out as a growth opportunity that won't break the bank.
Via Chartmill
Lantheus Appoints Julie Eastland as New Board Member
From Lantheus Holdings, Inc.
Via GlobeNewswire
NASDAQ:LNTH, an undervalued stock with good fundamentals.
Via Chartmill
NASDAQ:LNTH stands out as a growth opportunity that won't break the bank.
Via Chartmill
Bargain Hunting for Stocks: 2 Stocks to Buy in September
Via The Motley Fool
Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Why NASDAQ:LNTH Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
From Lantheus Holdings, Inc.
Via GlobeNewswire
NASDAQ:LNTH is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Lantheus Reports Second Quarter 2024 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Russell 2000 Marks Fifth Day Of Gains: What's Driving Surge In Small-Cap Stocks?
Via Benzinga
Topics ETFs
Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease
From Lantheus Holdings, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.